Influenza virus vaccine (GlaxoSmithKline)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInfluenza virus vaccine (GlaxoSmithKline)
Drug Alias NameFluarixalpha-RixFluarix-VBInflusplit SSWFluarix Trivalent
ClassificationVaccines > National Immunization Program > Non-immunization program vaccine(Class II)Vaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsInfluenza A virus infectionsOrthomyxoviridae InfectionsInfluenza, Human +[5] 
Global Approved IndicationsInfluenza A virus infectionsOrthomyxoviridae InfectionsInfluenza, Human +[4] 
Approved Indications in ChinaInfluenza A virus infectionsOrthomyxoviridae InfectionsInfluenza, Human
Original Approved Country/TerritoryMainland China
Original Approved Date2002/01/01
Country/TerritoryCzechiaBelgiumUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Biologicals SA
Inactive CompaniesGlaxosmithkline PlcNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsInfluenza A virus infectionsOrthomyxoviridae InfectionsInfluenza, Human +[4] 
Inactive IndicationsMeningococcal Infections

Other Information

ATC CodeJ07BB01
Related LinksN/A